Josep M. Campistol
Josep M. Campistol
Verified email at
Cited by
Cited by
Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
D Adams, A Gonzalez-Duarte, WD O’Riordan, CC Yang, M Ueda, ...
New England Journal of Medicine 379 (1), 11-21, 2018
Inotersen treatment for patients with hereditary transthyretin amyloidosis
MD Benson, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, ...
New England Journal of Medicine 379 (1), 22-31, 2018
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
K Suzuki, Y Tsunekawa, R Hernandez-Benitez, J Wu, J Zhu, EJ Kim, ...
Nature 540 (7631), 144-149, 2016
Sirolimus (RAPAMYCIN)-BASED therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine: 1, 2
CG Groth, L Bńckman, JM Morales, R Calne, H Kreis, P Lang, JL Touraine, ...
Transplantation 67 (7), 1036-1042, 1999
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial
T Coelho, LF Maia, AM da Silva, MW Cruz, V PlantÚ-Bordeneuve, ...
Neurology 79 (8), 785-792, 2012
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients
F Maduell, F Moreso, M Pons, R Ramos, J Mora-MaciÓ, J Carreras, ...
Journal of the American Society of Nephrology: JASN 24 (3), 487, 2013
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus
F Vincenti, S Friman, E Scheuermann, L Rostaing, T Jenssen, ...
American Journal of Transplantation 7 (6), 1506-1514, 2007
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft Recipients12
H Kreis, JM Cisterne, W Land, L Wramner, JP Squifflet, D Abramowicz, ...
Transplantation 69 (7), 1252-1260, 2000
In vivo amelioration of age-associated hallmarks by partial reprogramming
A Ocampo, P Reddy, P Martinez-Redondo, A Platero-Luengo, F Hatanaka, ...
Cell 167 (7), 1719-1733. e12, 2016
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial
FP Schena, MD Pascoe, J Alberu, M del Carmen Rial, R Oberbauer, ...
Transplantation 87 (2), 233-242, 2009
Sirolimus and secondary skin-cancer prevention in kidney transplantation
S Euvrard, E Morelon, L Rostaing, E Goffin, A Brocard, I Tromme, ...
New England Journal of Medicine 367 (4), 329-339, 2012
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
JM Campistol, J Eris, R Oberbauer, P Friend, B Hutchison, JM Morales, ...
Journal of the American Society of Nephrology 17 (2), 581-589, 2006
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
A Durrbach, JM Pestana, T Pearson, F Vincenti, VD Garcia, J Campistol, ...
American Journal of Transplantation 10 (3), 547-557, 2010
Interspecies chimerism with mammalian pluripotent stem cells
J Wu, A Platero-Luengo, M Sakurai, A Sugawara, MA Gil, T Yamauchi, ...
Cell 168 (3), 473-486. e15, 2017
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review
A Gutierrez-Dalmau, JM Campistol
Drugs 67, 1167-1198, 2007
In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation
HK Liao, F Hatanaka, T Araoka, P Reddy, MZ Wu, Y Sui, T Yamauchi, ...
Cell 171 (7), 1495-1507. e15, 2017
Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells
Y Xia, E Nivet, I Sancho-Martinez, T Gallegos, K Suzuki, D Okamura, ...
Nature cell biology 15 (12), 1507-1515, 2013
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma12
JM Campistol, A Gutierrez-Dalmau, JV Torregrosa
Transplantation 77 (5), 760-762, 2004
Case report of COVID‐19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation?
E Guillen, GJ Pineiro, I Revuelta, D Rodriguez, M Bodro, A Moreno, ...
American Journal of Transplantation 20 (7), 1875-1878, 2020
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
OB Suhr, T Coelho, J Buades, J Pouget, I Conceicao, J Berk, H Schmidt, ...
Orphanet journal of rare diseases 10 (1), 1-9, 2015
The system can't perform the operation now. Try again later.
Articles 1–20